Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 21.09.2026 1 Am J Clin Oncol 1 Ann Oncol 5 Ann Surg Oncol 2 Ann Thorac Surg 5 Cancer Cell 1 Cancer Chemother Pharmacol 3 Cancer Res 1 Cancer Sci 1 Chest 3 Clin Cancer Res 1 Clin Lung Cancer 1 Int J Oncol 1 J Comput Assist Tomogr 1 J Thorac Cardiovasc Surg 3 J Thorac Oncol 2 Lancet Oncol 1 Lung Cancer 2 Mol Carcinog 1 N Engl J Med 2 Nat Med 1 Oncogene 5 PLoS One 2 Science 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. PATEL A, Lee V, Nassar AH, Kim SY, et al
   EGFR Mutation Subtype and Risk of Brain Metastases From Non-Small Cell Lung Cancer in the Osimertinib Era: EGFR Subtype and Brain Metastases in NSCLC.
   Am J Clin Oncol. 2026 Sep 15. doi: 10.1097/COC.0000000000001376.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. PRUDENTE V, Bernatz S, Pai S, Atkins KM, et al
   Thymic radiation is associated with worse outcomes in patients with NSCLC.
   Ann Oncol. 2026;37:1345-1357.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. WATANABE T, Nomura K, Takamori S, Tane S, et al
   Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Sep 14. doi: 10.1245/s10434-026-20496.
   PubMed         Abstract available
   
   
4. HASHINOKUCHI A, Takamori S, Zhu J, Hannah H, et al
   Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.
   Ann Surg Oncol. 2026;33:8891-8899.
   PubMed         Abstract available
   
   
5. BONDZI-SIMPSON A, Seder CW, Wakeam E
   ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?
   Ann Surg Oncol. 2026;33:8703-8706.
   PubMed         Abstract available
   
   
6. ZOU J, Li P, Lei W, Han W, et al
   The Role of Surgery on the Treatment of Primary Pulmonary Sarcomas and Pulmonary Sarcomatoid Carcinoma.
   Ann Surg Oncol. 2026;33:8969-8980.
   PubMed         Abstract available
   
   
7. WAKEJIMA R, Ishibashi H, Asakawa A, Ishikawa Y, et al
   Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication.
   Ann Surg Oncol. 2026;33:8993-9001.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

8. SEDER CW, Bonnell LN, Yang CJ, Krantz SB, et al
   Association Between N1 Nodal Assessment, Upstaging, and Survival in Resected Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2026 Sep 18:S0003-4975(26)00940.
   PubMed         Abstract available
   
   
9. SEYOUM N, Eaton DB Jr, Rossetti NE, Ghani A, et al
   Non-small Cell Lung Cancer with and without Spread Through Air Spaces: Which Therapies are Associated with Improved Survival?
   Ann Thorac Surg. 2026 Sep 16:S0003-4975(26)00924.
   PubMed         Abstract available
   
   

   
   Cancer Cell

10. MEYERHOFF RR, Chen A, O'Brien J, Anadon CM, et al
    Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.
    Cancer Cell. 2026;44:1815-1831.
    PubMed         Abstract available
    
    
11. LATTANZI G, Hollern D
    Tumor-infiltrating plasma cell targets as a source for immunotherapies.
    Cancer Cell. 2026;44:1733-1734.
    PubMed         Abstract available
    
    
12. LIU L, Fei K, Wang J
    EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.
    Cancer Cell. 2026;44:1740-1742.
    PubMed         Abstract available
    
    
13. HAMILTON DA, Karunakaran MM, Coffelt SB
    gammadelta T cells BiTE back at small cell lung cancer.
    Cancer Cell. 2026 Sep 18:S1535-6108(26)00393-4. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    
14. NG J, You Y, Zhang TZ, Hess JB, et al
    gammadelta T cells modulate anti-tumor immunity in small cell lung cancer.
    Cancer Cell. 2026 Sep 18:S1535-6108(26)00392-2. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

15. ZHOU M, Tang F, Qu Z, Luo N, et al
    Targeting ALDH2 with Alda-1 to reverse cisplatin resistance in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2026;96:103.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. TONG X, Ji H
    A Barrier Betrayed: Hillock in Lung Squamous Cell Carcinoma.
    Cancer Res. 2026;86:4455-4456.
    PubMed         Abstract available
    
    
17. ZANG Z, Dorward DA, Ihuoma S, Akram AR, et al
    Label-Free Prediction of EGFR Mutation Status Using Fluorescence Lifetime Imaging and Deep Learning in Lung Adenocarcinoma.
    Cancer Res. 2026;86:4723-4733.
    PubMed         Abstract available
    
    
18. IZZO LT, Reyes T, Meesala S, Ireland AS, et al
    KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma.
    Cancer Res. 2026;86:4472-4496.
    PubMed         Abstract available
    
    

    
    Cancer Sci

19. MAO Q, Yu Y, Fang Y, Zhu S, et al
    Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non-Small Cell Lung Cancer.
    Cancer Sci. 2026 Sep 18. doi: 10.1111/cas.70535.
    PubMed         Abstract available
    
    

    
    Chest

20. JIA Y, Zhao J, Rivera MP
    Lung Cancer Screening Uptake Among Adults Newly Eligible Under the 2023 American Cancer Society Guideline Compared With USPSTF-Eligible Adults: A Nationwide Cross-Sectional Study.
    Chest. 2026 Sep 18:S0012-3692(26)06573-6. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

21. ZHANG Q, Tang X, Zhang ZF, Velikina R, et al
    Editor's Note: Nicotine Induces Hypoxia-Inducible Factor-1alpha Expression in Human Lung Cancer Cells via Nicotinic Acetylcholine Receptor-Mediated Signaling Pathways.
    Clin Cancer Res. 2026;32:4213.
    PubMed        
    
    
22. WANG VE, Ward NM, Kratz JR
    Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes.
    Clin Cancer Res. 2026 Sep 17. doi: 10.1158/1078-0432.CCR-26-2536.
    PubMed         Abstract available
    
    
23. AHN MJ, de Marinis F, Cho BC, Kim TM, et al
    Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.
    Clin Cancer Res. 2026 Sep 17. doi: 10.1158/1078-0432.CCR-26-0604.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

24. MITOME N, Kunimasa K, Nomura S, Kawabata K, et al
    A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skippin
    Clin Lung Cancer. 2026;27:54-58.
    PubMed         Abstract available
    
    

    
    Int J Oncol

25. LIANG Y, Zhuang J
    E3 ubiquitin ligase MAGI3?mediated TAZ ubiquitination suppresses the non?small cell lung cancer occurrence and development by targeting the Wnt pathway.
    Int J Oncol. 2026;69:126.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

26. KISTING AL, Kisting MA, Hinshaw JL, Couillard AB, et al
    Percutaneous Lung Biopsies Aided by Artificial Intelligence: A Comparison Between Computer and Physician-Chosen Biopsy Paths.
    J Comput Assist Tomogr. 2026;50:e01868.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

27. ADACHI H, Yamamoto H, Yamamoto K, Ito H, et al
    Reduced invasiveness of lobe-specific lymph node dissection in lung cancer surgery: Propensity score matching analysis using Japanese real-world data.
    J Thorac Cardiovasc Surg. 2026 Sep 18:S0022-5223(26)01303.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

28. BAUER TM, Martini JF, Besse B, Lin CC, et al
    Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.
    J Thorac Oncol. 2026 Sep 16:104202. doi: 10.1016/j.jtho.2026.104202.
    PubMed         Abstract available
    
    
29. DEVARAKONDA S, Hoang M, Sankararaman S, Skidmore ZL, et al
    Genomic and transcriptomic features of relapsed small cell lung cancer.
    J Thorac Oncol. 2026 Sep 16:104201. doi: 10.1016/j.jtho.2026.104201.
    PubMed         Abstract available
    
    
30. WU YL, Majem M, John T, Grohe C, et al
    Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].
    J Thorac Oncol. 2026 Sep 13:104179. doi: 10.1016/j.jtho.2026.104179.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

31. ZHANG M, Wisnivesky JP, Qiu M, Danesh Yazdi M, et al
    Long-term exposure to wildfire-related PM(2.5) and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study.
    Lancet Oncol. 2026 Sep 15:S1470-2045(26)00295.
    PubMed         Abstract available
    
    
32. PATODIA S
    2026 World Conference on Lung Cancer.
    Lancet Oncol. 2026 Sep 17:S1470-2045(26)00480.
    PubMed        
    
    

    
    Lung Cancer

33. ROESCH RM, Utz M, Eichhorn F, Christopoulos P, et al
    Reassessing surgical resection in small cell lung cancer in the multimodal treatment era.
    Lung Cancer. 2026;221:109600.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

34. ZHANG J, Zhang C, Jiang G, Liu X, et al
    The CRABP2-MDK Signaling Axis Promotes Lung Adenocarcinoma (LUAD) Progression and Highlights Prognostic Biomarkers.
    Mol Carcinog. 2026;65:1163-1182.
    PubMed         Abstract available
    
    
35. ZHANG J, Chen Q, Wu Y, Han Y, et al
    LACTB2 Promotes the Growth and Migration of Non-Small Cell Lung Cancer By Regulating Mitochondrial Function.
    Mol Carcinog. 2026 Sep 15. doi: 10.1002/mc.70180.
    PubMed         Abstract available
    
    

    
    N Engl J Med

36. ZHAO Y, Liu H, Meng X, Liu Z, et al
    Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
    N Engl J Med. 2026 Sep 12. doi: 10.1056/NEJMoa2610229.
    PubMed         Abstract available
    
    

    
    Nat Med

37. AI X, Song Z, Wu L, Zhou A, et al
    Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS(G12D) mutations: a phase 1 trial.
    Nat Med. 2026;32:3302-3312.
    PubMed         Abstract available
    
    
38. PRELAJ A, Miskovic V, Sacco M, Ferrarin A, et al
    Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC.
    Nat Med. 2026;32:3235-3247.
    PubMed         Abstract available
    
    

    
    Oncogene

39. TAKAMORI S, Haratake N, Bhattacharya A, Ozawa H, et al
    M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.
    Oncogene. 2026;45:4088-4100.
    PubMed         Abstract available
    
    

    
    PLoS One

40. ZHANG L, Zhuo D, Wu X, He Y, et al
    Multi-view attention-based deep learning for benign-malignant classification of pulmonary nodules.
    PLoS One. 2026;21:e0357963.
    PubMed         Abstract available
    
    
41. ESPINOZA A, Goles E, Montalva-Medel M
    Boolean-network simplification and rule fitting to unravel chemotherapy resistance in non-small cell lung cancer.
    PLoS One. 2026;21:e0357764.
    PubMed         Abstract available
    
    
42. YANG J, Liu J, Zhao G, Li H, et al
    Safety profile of entrectinib in NSCLC: Multi-source pharmacovigilance analysis using FAERS and JADER.
    PLoS One. 2026;21:e0358331.
    PubMed         Abstract available
    
    
43. FENG H, Hu X, Zhang L, Zhang Q, et al
    A novel one-step multiplex PCR method (OS-MPCR) for efficient NGS library preparation in cancer.
    PLoS One. 2026;21:e0357776.
    PubMed         Abstract available
    
    
44. GUO H, Liu L, Lu Y, Ma Y, et al
    Prognostic value of melatonin-related signature genes in lung adenocarcinoma.
    PLoS One. 2026;21:e0357584.
    PubMed         Abstract available
    
    

    
    Science

45. CHANOCK S
    In search of past genetics.
    Science. 2026;393:1190.
    PubMed         Abstract available
    
    
46. LOPICCOLO J, Micheletti S, Shi J, Wang W, et al
    Germline EGFR T790M mutation and lung cancer risk.
    Science. 2026;393:eaec0473.
    PubMed         Abstract available
    
    

    
    Thorax

47. ZITRICKY F, Sundquist K, Sundquist J, Forsti A, et al
    Increase in second primary lung cancers in a nation-wide cohort study from Sweden.
    Thorax. 2026;81:981-987.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum